You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 24, 2024

Details for New Drug Application (NDA): 019543

✉ Email this page to a colleague

« Back to Dashboard

NDA 019543 describes ELOCON, which is a drug marketed by Organon and is included in three NDAs. Additional details are available on the ELOCON profile page.

The generic ingredient in ELOCON is mometasone furoate. There are thirty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for 019543
Ingredient:mometasone furoate
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 019543

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:OINTMENT;TOPICALStrength0.1%
Approval Date:Apr 30, 1987TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.